Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Morocco has been experiencing steady growth in recent years, driven by various factors such as an aging population, increasing incidence of cardiovascular diseases, and rising awareness about the benefits of preventive healthcare.
Customer preferences: Moroccan customers have shown a growing preference for oral anticoagulants over injectable ones, owing to their convenience and ease of use. Additionally, there has been an increasing demand for generic versions of anticoagulants, driven by cost considerations.
Trends in the market: One of the key trends in the Anti-Coagulants market in Morocco is the growing adoption of direct oral anticoagulants (DOACs) over traditional vitamin K antagonists (VKAs). DOACs offer several advantages over VKAs, including a lower risk of bleeding and fewer drug interactions. Another trend is the increasing use of anticoagulants for the prevention of stroke in patients with atrial fibrillation.
Local special circumstances: Morocco has a high prevalence of cardiovascular diseases, which is one of the main drivers of growth in the Anti-Coagulants market. Additionally, the country has a rapidly aging population, which is expected to further increase the demand for anticoagulants in the coming years. However, there are also challenges in the market, including a lack of public awareness about the benefits of anticoagulants and a shortage of skilled healthcare professionals.
Underlying macroeconomic factors: Morocco has a relatively stable economy and a growing middle class, which is expected to drive demand for healthcare services, including anticoagulants. Additionally, the government has been investing in healthcare infrastructure and increasing access to healthcare services, which is expected to further boost demand for anticoagulants. However, there are also challenges such as a lack of healthcare insurance coverage for some segments of the population, which may limit access to anticoagulants.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
